Abstract
Topoisomerase I inhibitors constitute a new class of anti-cancer agents. Recently, topotecan and irinotecan were registered for clinical use in ovarian cancer and colorectal cancer respectively. Cytotoxicity of topoisomerase I inhibitors is S-phase specific, and in vitro and in vivo studies have suggested that, for efficacy, prolonged exposure might be more important than short-term exposure to high concentration. Clinical development of those topoisomerase I inhibitors that have reached this stage is also focused on schedules aiming to achieve prolonged exposure. In this review, we summarize all published preclinical studies on this topic for topoisomerase I inhibitors in clinical development, namely 20-S-camptothecin, 9-nitro-camptothecin, 9-amino-camptothecin, topotecan, irinotecan and GI147211. In addition, preliminary data on clinical studies concerning this topic are also reviewed. The data suggest that prolonged exposure may indeed be relevant for anti-tumour activity. However, the optimal schedule is yet to be determined. Finally, clinical data are yet too immature to draw definitive conclusions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gerrits, C., de Jonge, M., Schellens, J. et al. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 76, 952–962 (1997). https://doi.org/10.1038/bjc.1997.491
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.491
This article is cited by
-
Fabrication and characterization of sterically stabilized liposomes of topotecan
Future Journal of Pharmaceutical Sciences (2020)
-
A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo
Cell Death & Disease (2018)
-
Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration
Cancer Chemotherapy and Pharmacology (2017)
-
Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans
Cancer Chemotherapy and Pharmacology (2014)
-
A phase II trial of oral gimatecan for recurrent glioblastoma
Journal of Neuro-Oncology (2013)